Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

未开盘 12-04 16:00:00 EST

22.82

+0.98

+4.49%

盘后22.73

-0.09-0.39%

19:59 EST

最高23.00	最低21.47	成交量339.60万
今开21.55	昨收21.84	日振幅7.01%
总市值23.91亿	流通市值21.72亿	总股本1.05亿
成交额7,665万	换手率3.57%	流通股本9,517万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":22.82,"timestamp":1764882000000,"preClose":21.84,"halted":0,"volume":3395986,"hourTrading":{"tag":"盘后","latestPrice":22.73,"preClose":22.82,"latestTime":"19:59 EST","volume":62628,"amount":1427712.45,"timestamp":1764896396015},"delay":0,"floatShares":95167800,"shares":104787187,"eps":-2.771059,"marketStatus":"未开盘","change":0.98,"latestTime":"12-04 16:00:00 EST","open":21.55,"high":23,"low":21.47,"amount":76646633.131178,"amplitude":0.070055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.771059,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1764925200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":865396800000,"exchange":"NASDAQ","adjPreClose":21.84,"preHourTrading":{"tag":"盘前","latestPrice":21.56,"preClose":21.84,"latestTime":"09:28 EST","volume":14542,"amount":313967.5968,"timestamp":1764858481044},"postHourTrading":{"tag":"盘后","latestPrice":22.73,"preClose":22.82,"latestTime":"19:59 EST","volume":62628,"amount":1427712.45,"timestamp":1764896396015},"volumeRatio":1.116065,"impliedVol":0.9839,"impliedVolPercentile":0.672},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"1110568516","title":"Sarepta Therapeutics：计划在年底前启动第8组，并预计在2026年下半年完成主要终点数据收集","url":"https://stock-news.laohu8.com/highlight/detail?id=1110568516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110568516?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:01","pubTimestamp":1764079281,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics：计划在年底前启动第8组，并预计在2026年下半年完成主要终点数据收集","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4139","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","BK4585","IE00BJJMRZ35.SGD","SRPT"],"gpt_icon":0},{"id":"1192840225","title":"Sarepta 提供关于 Srp-1003 的进展更新，这是一种用于肌强直性肌肉病 1 型的研究性 siRNA 治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1192840225","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192840225?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:31","pubTimestamp":1763987488,"startTime":"0","endTime":"0","summary":"Sarepta 提供关于 Srp-1003 的进展更新，这是一种用于肌强直性肌肉病 1 型的研究性 siRNA 治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","IE00BJJMRZ35.SGD","SRPT","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1197238185","title":"Hhs：新的Elevidys安全警告将适应症限制在4岁及以上、具有DMD基因确认突变的步态患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1197238185","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197238185?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:07","pubTimestamp":1763147266,"startTime":"0","endTime":"0","summary":"Hhs：新的Elevidys安全警告将适应症限制在4岁及以上、具有DMD基因确认突变的步态患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","SRPT","IE00BJJMRZ35.SGD","BK4585","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1178897853","title":"卫生与公共服务部：FDA批准新的安全警告及修订指示，限制Elevidys的使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1178897853","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178897853?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:00","pubTimestamp":1763146813,"startTime":"0","endTime":"0","summary":"卫生与公共服务部：FDA批准新的安全警告及修订指示，限制Elevidys的使用，以应对致命肝损伤的报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B2B36J28.USD","IE0009355771.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","SRPT","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2583063718","title":"Sarepta Therapeutics, Inc.盘中异动 临近午盘股价大涨5.11%报18.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583063718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583063718?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:30","pubTimestamp":1763137818,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日00时30分，Sarepta Therapeutics, Inc.股票出现异动，股价大幅上涨5.11%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，Cidara Therapeutics, Inc.、Cypherpunk Technologies Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Cypherpunk Technologies Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为980.06%、247.23%、137.65%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cypherpunk Technologies Inc.、Hcw Biologics Inc.，振幅分别为101.46%、94.31%、59.44%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003018a4a209fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003018a4a209fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFTCPJ56.SGD","IE0002141913.USD","LENZ","IE00B2B36J28.USD","BK4539","BK4585","IE0009355771.USD","SRPT","BK4007","IE00BJJMRZ35.SGD","BK4139","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1154277843","title":"异动解读 | 瑞穗证券上调评级，Sarepta Therapeutics盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154277843","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154277843?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:55","pubTimestamp":1762354544,"startTime":"0","endTime":"0","summary":"生物制药公司Sarepta Therapeutics今日盘中大涨5.12%，引发市场广泛关注。根据最新报告，瑞穗证券将Sarepta Therapeutics的投资评级上调至\"跑赢大盘\"，同时将目标价从19美元大幅上调至26美元，涨幅高达36.8%。Sarepta Therapeutics作为一家专注于开发用于治疗罕见疾病的创新疗法的生物制药公司，在基因治疗领域具有较强的竞争力。这次评级的提升不仅可能吸引更多投资者关注该公司，还可能为Sarepta Therapeutics后续的融资和业务发展创造有利条件。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1112951067","title":"异动解读 | 瑞穗证券上调评级，Sarepta Therapeutics盘前大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112951067","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112951067?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:04","pubTimestamp":1762337070,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司Sarepta Therapeutics股价大涨5.06%，引发市场关注。此次股价上涨主要受益于华尔街知名投资银行瑞穗证券对该公司的积极评价。根据最新报告，瑞穗证券将Sarepta Therapeutics的投资评级上调至\"跑赢大盘\"，同时将目标价从19美元大幅上调至26美元，这一举动显著提振了投资者信心。瑞穗证券的评级上调反映了分析师对Sarepta Therapeutics未来发展前景的看好。作为一家专注于开发用于治疗罕见疾病的创新疗法的生物制药公司，Sarepta Therapeutics在基因治疗领域具有较强的竞争力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1178760479","title":"Sarepta Therapeutics Inc：瑞穗证券将投资评级上调至“跑赢大盘”，目标价从19美元上调至26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178760479","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178760479?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:03","pubTimestamp":1762336993,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc：瑞穗证券将投资评级上调至“跑赢大盘”，目标价从19美元上调至26美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","IE00BJJMRZ35.SGD","SRPT","IE0009355771.USD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"1114173553","title":"异动解读 | Sarepta Therapeutics股价夜盘暴跌5.06%，肌肉疾病新药确证试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1114173553","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114173553?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:29","pubTimestamp":1762306182,"startTime":"0","endTime":"0","summary":"美国生物技术公司Sarepta Therapeutics周二夜盘股价大跌5.06%，引发市场广泛关注。根据公司最新公布的消息，Sarepta Therapeutics一款已获批准的针对杜氏肌营养不良症的靶向基因疗法药物在确证性试验中未能达到主要目标。杜氏肌营养不良症是一种罕见的遗传性肌肉退化疾病，目前尚无根治方法。Sarepta的这款药物曾被寄予厚望，有望为患者带来新的治疗选择。市场对这一负面消息反应强烈，导致公司股价在夜盘交易中大幅下挫。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"2580903753","title":"Sarepta Thera药物研究未达标，股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2580903753","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580903753?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:44","pubTimestamp":1762267440,"startTime":"0","endTime":"0","summary":"生物技术公司Sarepta Therapeutics（SRPT）股价暴跌32.9%，此前该公司报告其针对杜氏肌营养不良症的两种靶向基因疗法的后期研究未能达到主要目标。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-04/doc-infwhekf1286929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B2B36J28.USD","IE0002141913.USD","BK4139","SINA","IE00BJJMRZ35.SGD","BK4585","SRPT","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD"],"gpt_icon":0},{"id":"1156106306","title":"周二关注的股票：Palantir、Sarepta、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=1156106306","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156106306?lang=zh_cn&edition=full","pubTime":"2025-11-04 18:48","pubTimestamp":1762253321,"startTime":"0","endTime":"0","summary":"Palantir ：预售时股价下跌。这家数据分析公司报告了又一个创纪录的季度收入，但由于在2025年迄今股价已翻倍，股票的定价已达完美标准。Sarepta Therapeutics ：股价大幅下跌，因为这家生物科技公司表示，针对一种罕见肌肉萎缩疾病的两种疗法的长期试验结果未能达到统计学意义。辉瑞 、Spotify 、优步  和万豪酒店  计划在盘前公布财报，而美国超微公司  则将在收盘后发布业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"240d82993489181f2c14fbceebaca07a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","IE00B1BXHZ80.USD","LU1069344957.HKD","LU2362541513.USD","LU0225771236.USD","LU2125909593.SGD","GB00BDT5M118.USD","LU2244417387.USD","LU2265009873.SGD","BK4567","LU0889565833.HKD","BK4550","LU1064131342.USD","LU1035775433.USD","LU0882574139.USD","LU2168564222.USD","IE00BHPRN162.USD","LU2430703178.SGD","LU0823411888.USD","LU2471134952.CNY","LU1791710400.SGD","LU0289960550.SGD","BK4587","HK0000306701.USD","LU0256863902.USD","LU2023250330.USD","LU0276348264.USD","LU0964807845.USD","LU2322448791.USD","SPOT","LU0225283273.USD","LU2065171311.SGD","LU2592432038.USD","LU0210533765.USD","IE00BN29S564.USD","LU0348723411.USD","LU2505996509.AUD","LU1935043023.USD","SG9999014914.USD","LU0265550359.USD","LU0306806265.USD","LU2458330169.SGD","LU2896262040.SGD","BK4535","LU0061475181.USD","LU2242650005.HKD","LU0048584097.USD","LU1861214812.USD","LU1923622291.USD","IE00BK4W5M84.HKD","LU0823434583.USD","LU1983260115.SGD","LU2361044949.HKD","LU2602419157.SGD","LU1861220033.SGD","LU0820562030.AUD","BK4549","IE00B19Z8X17.USD","IE00BJJMRY28.SGD","LU1791710582.SGD","SG9999018865.SGD","LU2463028550.USD","LU0225284248.USD","LU2097344357.USD","LU2237438978.USD","IE00BJTD4V19.USD","SG9999015952.SGD","LU0354030511.USD","LU2860962120.EUR","SG9999002224.SGD","LU2272731782.SGD","IE00BDRTCR15.USD","LU0353189763.USD","LU1934455194.USD","BK4022","LU0070217475.USD","LU0234570918.USD","LU0289961442.SGD","LU1242518857.USD","BK4230","LU0476273544.USD","LU0267386448.USD","LU0274383776.USD","LU1989764748.USD","LU0256863811.USD","LU1951198990.SGD","NVDU","LU1127390331.HKD","BK4605","LU2098885051.SGD","LU1778281490.HKD","LU1934455863.HKD","2NVD.UK","LU2458330243.SGD","LU0640476718.USD","LU0210536198.USD","LU0215105999.USD","LU2420271590.USD","LU2211815571.USD","BK4099","LU0061474705.USD","IE00BFSS7M15.SGD","LU0354030438.USD","IE00BWXC8680.SGD","LU1674673691.USD","LU0238689110.USD","LU2362540622.SGD","BK4512","BK4023","LU1267930490.SGD","LU0557290698.USD","LU1116320737.USD","LU1821325948.USD","LU0081259029.USD","LU1914381329.SGD","LU0061474960.USD","LU0444971666.USD","IE0002270589.USD","LU1084165304.USD","LU1861558580.USD","IE00BYXW3230.USD","BK4612","LU0251132253.USD","LU0096364046.USD","LU0109392836.USD","LU1712237335.SGD","LU1066051498.USD","LU1880398471.USD","LU0985481810.HKD","BK4551","LU1280957306.USD","LU0289739699.SGD","IE00BJLML261.HKD","IE0009356076.USD","LU1861215975.USD","SG9999014906.USD","SG9999015978.USD","LU2491050071.SGD","SGXZ81514606.USD","IE00B1XK9C88.USD","LU1894683348.USD","LU2237957811.SGD","LU0353189680.USD","LU1267930573.SGD","LU2552382132.HKD","LU0444973449.USD","IE00BMPRXN33.USD","IE00B19Z3B42.SGD","BK4527","BK4141","LU0211327993.USD","LU2357305700.SGD","LU0957808578.USD","BK4599","LU0724617625.USD","BK4604","LU1244550494.USD","LU2746668461.USD","LU1267930730.SGD","SG9999001176.SGD","LU0345770308.USD","LU0128525929.USD","LU0079474960.USD","LU2413666699.HKD","LU0823414478.USD","LU1861219969.SGD","LU2272731865.HKD","LU2491049909.HKD","LU2089284900.SGD","LU1066051225.USD","LU1057294990.SGD","LU0965509101.SGD","LU1551013342.USD","BK4007","LU0861579265.USD","IE00BZ199S13.USD","LU0265550946.USD","LU2361044865.SGD","LU0985320562.USD","LU0096362180.USD","LU2461242641.AUD","SG9999015986.USD","LU2023251221.USD","LU0310800379.SGD","LU1814569148.SGD","LU0211328371.USD","LU0965509010.AUD","LU2063271972.USD","LU1935042488.USD","LU1721428933.USD","LU0965508806.USD","LU1699723380.USD","LU0456855351.SGD","IE00BJJMRZ35.SGD","LU0511384066.AUD","LU0689472784.USD","HK0000320223.HKD","LU2326559502.SGD","BK4511","LU0198837287.USD","LU0345769631.USD","IE00B894F039.SGD","IE0004445239.USD","LU2756315318.SGD","LU2250418816.HKD","LU0122379950.USD","BK4533","LU1935043536.SGD","LU2097829019.USD","UBER","BK4547","BK4139","IE00BMPRXR70.SGD","LU1992135399.USD","LU0820561818.USD","IE00BZ1G4Q59.USD","NVD2.UK","NVDY","LU2357125470.USD","IE00B775H168.HKD","LU1119994496.HKD","LU1989764664.SGD","LU1861127337.USD","LU0788109477.HKD","LU2361045086.USD","LU1244550577.SGD","LU2381873111.SGD","HK0000320264.USD","BK4614","IE00B7KXQ091.USD","NVDS.UK","TSLA","IE00B95QR487.USD","LU0787776722.HKD","LU1992135472.HKD","BK4573","LU0057025933.USD","LU0308772762.SGD","SGXZ99366536.SGD","SG9999000418.SGD","LU1917777945.USD","IE0009355771.USD","LU1642822529.SGD","BK4529","IE00B45NX917.SGD","LU0683600562.USD","LU2430703251.USD","IE00BQXX3F31.USD","LU2237957902.USD","LU0719512351.SGD","LU0106261372.USD","BK4585","LU0310799852.SGD","SRPT","LU1242518931.SGD","SG9999015358.SGD","LU0943347566.SGD","BK4555","LU0820561909.HKD","MAR","LU1066051811.HKD","LU2360106780.USD","LU2552382058.USD","LU2271345857.HKD","LU2092937148.SGD","LU2931357623.SGD","LU2417539215.USD","LU0957791311.USD","LU2433249047.HKD","LU0942090050.USD","IE00B19Z8W00.USD","LU1244550221.USD","LU0124676726.USD","IE00BK4W5L77.USD","IE00B19Z9Z06.USD","LU0323591593.USD","BK4613","BK4108","LU0472753341.HKD","LU0823434740.USD","LU2552382215.SGD","LU1232071149.USD","SG9999011175.SGD","LU2191332357.HKD","LU1366192091.USD","BK4574","LU1720051017.SGD","IE00BJJMRX11.SGD","LU1935042215.USD","BK4588","IE00B19Z3581.USD","LU1804176565.USD","BK4503","LU1839511570.USD","IE00BQXX3D17.EUR","BK4543","LU0154236417.USD","LU0345769128.USD","LU0029864427.USD","LU1435385759.SGD","LU2462157665.USD","NVD3.UK","IE0034235295.USD","NVDX","IE00BKPKM429.USD","IE0002141913.USD","LU0080751232.USD","SG9999003800.SGD","LU1496350502.SGD","NVDD","LU0321505868.SGD","IE00BFSS8Q28.SGD","LU2543165471.USD","LU0868494708.USD","IE00B5949003.HKD","IE00BJT1NW94.SGD","LU1935042991.SGD","LU2290526834.HKD","LU0823421416.USD","IE00BJTD4N35.SGD","LU2097344431.USD","LU1023059063.AUD","LU2065170008.USD","LU0342679015.USD","IE00BLSP4452.SGD","LU0127658192.USD","LU1868837300.USD","LU2125909916.SGD","LU1316542783.SGD","LU0390134368.USD","LU1894683264.USD","LU1633808545.USD","LU0006306889.USD","SG9999014898.SGD","SG9999015341.SGD","IE0034235188.USD","LU0306807586.USD","LU2294711713.HKD","LU0417517546.SGD","LU1880398554.USD","LU0965509283.SGD","LU1261432733.SGD","LU0466842654.USD","BK4571","SG9999014559.SGD","LU2168563687.JPY","LU0203202063.USD","IE0005OL40V9.USD","LU1551013425.SGD","IE00BZ9MQY76.HKD","LU1868837136.USD","LU2089985449.USD","SG9999018857.SGD","LU2487616109.SGD","LU0689626769.HKD","IE00BQXX3C00.GBP","LU2471134523.USD","LU2360107325.USD","IE00BKDWB100.SGD","3NVD.UK","LU2413666426.HKD","IE00B2B36J28.USD","LU2065171402.SGD","SGXZ57979304.SGD","LU0494093205.USD","LU0158827948.USD","LU0316494557.USD","LU0708995401.HKD","IE00B4JS1V06.HKD","LU0109391861.USD","LU1883839398.USD","LU0158827781.USD","LU2473716301.USD","LU2213496289.HKD","LU2746668974.SGD","LU2108987350.USD","BK4534","LU2125154778.USD","LU1303367103.USD","SG9999014542.SGD","SG9999004303.SGD","LU2264538146.SGD","LU2106854487.HKD","LU2125154935.USD","LU1951200564.SGD","LU2242649171.HKD","BK4608","SG9999001176.USD","IE0034235303.USD","SNVD.UK","LU1548497426.USD","IE00BFMHRM44.USD","LU0528227936.USD","LU2750360641.GBP","LU1145028129.USD","SG9999014567.USD","LU1116320901.HKD","LU1718418525.SGD","IE00BKVL7J92.USD","LU0072462426.USD","LU0321505439.SGD","IE00BD0PCF45.HKD","LU2403377893.USD","LU2054465674.USD","LU2236285917.USD","IE00B1G9WX41.USD","LU2360107168.USD","LU2111349929.HKD","LU2092627202.USD","LU0107464264.USD","LU1066053197.SGD","LU2322448957.HKD","BK4592","LU0823421333.USD","LU2065169927.USD","IE00BSNM7G36.USD","LU1366333091.USD","LU2471134796.USD","NVIW.SI","LU2087621335.USD","BK4581","HK0000306685.HKD","LU1429558221.USD","LU0056508442.USD","LU0187121727.USD","LU2089283258.USD","PFE","IE00BDCRKT87.USD","LU2028103732.USD","LU1868836914.USD","LU1623119135.USD","LU2125909247.SGD","LU1815336760.USD","SG9999017495.SGD","LU1868836591.USD","LU1989772923.USD","IE00BBT3K403.USD","LU0345768153.USD","BK4516","BK4575","LU2249611893.SGD","LU2430703095.HKD","BK4579","LU0868494617.USD","LU0058720904.USD","BK4505","LU2125909759.SGD","LU1989772840.SGD","LU0979878070.USD","NVDS","LU2360032135.SGD","LU2471134879.HKD","LU1037948541.HKD","LU1323610961.USD","SGXZ51526630.SGD","LU1803068979.SGD","IE00B19Z9505.USD","LU2087625088.SGD","BK4554","NVDL","LU1496350171.SGD","LU2362541273.HKD","BK4532","IE00BLSP4239.USD","LU0175139822.USD","LU2506951792.HKD","BK4536","PLTR","LU2247934214.USD","BK4568","LU0053666078.USD","LU1934455277.USD","IE00BMPRXQ63.HKD","TSLL","LU0347712357.USD","BK4566","SG9999002232.USD","LU1674673428.USD","BK4548","SG9999015945.SGD","LU0097036916.USD","LU2286300806.USD","LU0289739343.SGD","LU1974910355.USD","IE00B19Z9P08.USD","LU1852331112.SGD","LU0672654240.SGD","LU1815333072.USD","LU0234572021.USD","LU0823414551.USD","LU2077746001.SGD","LU0345770993.USD","LU2756315664.SGD","LU0786609619.USD","SG9999014575.USD","LU0266013472.USD","LU0170899867.USD","IE0004445015.USD","NVDA","IE00BD6J9T35.USD","LU0157215616.USD","LU0642271901.SGD","IE00BFTCPJ56.SGD","LU2505996681.GBP","IE00B3M56506.USD","SGXZ23171101.USD","NVD","LU2491050154.USD","LU2452424414.USD","LU0077335932.USD","LU2023250504.SGD","LU0320765059.SGD","LU1571399168.USD","LU2083900584.USD","LU1861559042.SGD","IE0004086264.USD","TSYW.SI","AMD","LU0708994859.HKD","SGXZ31699556.SGD","LU2168564149.EUR","LU1923623000.USD","SG9999014880.SGD","IE00B7SZLL34.SGD","LU2168564065.EUR","LU2750360997.AUD","SG9999013999.USD","LU1720051108.HKD","LU1629891620.HKD","SG9999001424.SGD","LU0345768740.USD","LU2456880835.USD","LU2272731600.USD","IE000M9KFDE8.USD","LU0082616367.USD","LU0069063385.USD","BK4142","IE0004091025.USD","IE00B0T0GQ85.USD","LU0094547139.USD","LU1037948897.HKD","LU1988902786.USD","LU0210528500.USD","LU1923622614.USD","LU0203201768.USD","LU2168564495.EUR","BK4598"],"gpt_icon":0},{"id":"1101705682","title":"异动解读 | Sarepta Therapeutics盘前暴跌35.83%，杜氏肌营养不良症基因疗法临床试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1101705682","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101705682?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:08","pubTimestamp":1762247316,"startTime":"0","endTime":"0","summary":"生物科技公司Sarepta Therapeutics今日盘前股价暴跌35.83%，引发市场广泛关注。这一显著跌幅主要源于公司公布其针对杜氏肌营养不良症的两种基因疗法AMONDYS 45和VYONDYS 53的后期临床试验未能达到主要目标。Sarepta表示，新冠疫情严重影响了受试者以及整体试验结果，增加了研究的复杂性。然而，由于近期监管审查力度加大，加上与公司另一项基因疗法Elevidys相关的安全担忧，Sarepta今年以来的市值已损失约80%。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1111498092","title":"Sarepta Therapeutics股价在盘前交易中暴跌36.6%，因肌肉萎缩症药物试验未达关键目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1111498092","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111498092?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:04","pubTimestamp":1762247051,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics股价在盘前交易中暴跌36.6%，因其针对肌肉萎缩症的药物试验未能达到关键目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4139","SRPT","BK4585","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1177299388","title":"异动解读 | Sarepta Therapeutics夜盘大跌36.20%，DMD基因疗法临床试验未达主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1177299388","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177299388?lang=zh_cn&edition=full","pubTime":"2025-11-04 09:03","pubTimestamp":1762218202,"startTime":"0","endTime":"0","summary":"生物科技公司Sarepta Therapeutics在夜盘交易中股价大跌36.20%，引发市场广泛关注。这一显著跌幅主要源于公司公布其针对杜氏肌营养不良症的两种基因疗法AMONDYS 45和VYONDYS 53的后期临床试验未能达到主要目标。Sarepta表示，新冠疫情严重影响了受试者以及整体试验结果，增加了研究的复杂性。然而，由于近期监管审查力度加大，加上与公司另一项基因疗法Elevidys相关的安全担忧，Sarepta今年以来的市值已损失约80%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1171540689","title":"美股夜盘 | Palantir绩后跌超4%，纳微半导体跌超14%；Sarepta暴跌36%，iHeartMedia暴涨59%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171540689","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171540689?lang=zh_cn&edition=full","pubTime":"2025-11-04 09:00","pubTimestamp":1762218018,"startTime":"0","endTime":"0","summary":"11月4日，美股夜盘时段，$Palantir$绩后跌超4%，公司三季度营收超预期，上调全年营收指引。$纳微半导体$夜盘跌超14%，第三季度业绩低于预期，业绩指引疲软。精准基因领军者Sarepta夜盘暴跌36%，DMD基因疗法临床试验未达预期。Cipher Mining夜盘跌超4%，其股价上一交易日涨超22%，公司与$亚马逊$签署为期十五年、价值55亿美元的数据中心租赁协议。$Hims & Hers Health$夜盘涨超6%， Q3营收同比增长49%，调整后EBITDA大幅攀升。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIFR","SRPT","PLTR","DENN","IHRT","NVTS"],"gpt_icon":0},{"id":"2580222689","title":"盘后异动 | 精准基因领军者Sarepta暴跌36%，DMD基因疗法临床试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2580222689","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580222689?lang=zh_cn&edition=full","pubTime":"2025-11-04 07:47","pubTimestamp":1762213645,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在针对杜氏肌营养不良症的两种基因疗法AMONDYS 45以及VYONDYS 53的后期临床试验未能达到其主要目标后，专注于罕见病疗法的全球知名生物科技公司Sarepta Therapeutics的股价大幅下跌，该股在美股盘后交易中一度暴跌超过39%。本次Sarepta股价盘后大跌，核心是至关重要的三期临床失败叠加管线不确定性急剧上升，而不是单纯的财务数据波动。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364772.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"精准基因领军者Sarepta盘后暴跌，DMD基因疗法临床试验未达预期","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SRPT","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","BK4139"],"gpt_icon":1},{"id":"1169199118","title":"Sarepta高管表示FDA领导最近提到0.05对于罕见疾病相对任意，指出0.09可能被接受 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1169199118","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169199118?lang=zh_cn&edition=full","pubTime":"2025-11-04 06:33","pubTimestamp":1762209195,"startTime":"0","endTime":"0","summary":"Sarepta高管表示FDA领导最近提到0.05对于罕见疾病相对任意，指出0.09可能被接受 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","IE00BJJMRZ35.SGD","SRPT","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1140775381","title":"Sarepta高管表示0.09意味着91%的时间能见到药物效果，对罕见疾病尤为重要","url":"https://stock-news.laohu8.com/highlight/detail?id=1140775381","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140775381?lang=zh_cn&edition=full","pubTime":"2025-11-04 06:33","pubTimestamp":1762209191,"startTime":"0","endTime":"0","summary":"Sarepta高管表示，0.09这个数字意味着在91%的情况下，可以观察到药物的治疗效果，这对罕见疾病的治疗具有特别重要的意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK4585","SRPT","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"1117347782","title":"异动解读 | Sarepta Therapeutics盘后大跌20.65%，杜兴氏基因疗法研究未达主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1117347782","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117347782?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:33","pubTimestamp":1762205598,"startTime":"0","endTime":"0","summary":"生物技术公司Sarepta Therapeutics股价在盘后交易中暴跌20.65%，引发市场广泛关注。这一显著跌幅主要源于公司公布其杜氏肌营养不良症基因靶向疗法的后期研究未能达到主要目标。据悉，Sarepta公司进行的这项研究涉及两种针对杜兴氏症的基因靶向疗法Casimersen和golodirsen。该研究在225名6至13岁的男孩中进行，这些患者的杜兴氏症可以通过跳过45或53号外显子来治疗。尽管研究结果令人失望，但Sarepta公司表示，这些疗法的耐受性良好，没有出现新的安全问题。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b9a3cd8af26b3e0950fd6786b7346c9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1128569531","title":"Sarepta Therapeutics Inc：Elevidys标签讨论进展顺利，预计很快结束","url":"https://stock-news.laohu8.com/highlight/detail?id=1128569531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128569531?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:06","pubTimestamp":1762203977,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc：Elevidys标签讨论进展顺利，预计很快结束","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK4139","IE0009355771.USD","SRPT","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":0.0893},{"period":"1month","weight":0.4086},{"period":"3month","weight":0.2197},{"period":"6month","weight":-0.4694},{"period":"1year","weight":-0.8196},{"period":"ytd","weight":-0.8123}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.051964},{"month":2,"riseRate":0.615385,"avgChangeRate":0.046164},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.008053},{"month":4,"riseRate":0.307692,"avgChangeRate":0.010895},{"month":5,"riseRate":0.692308,"avgChangeRate":0.132774},{"month":6,"riseRate":0.692308,"avgChangeRate":0.049251},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.004395},{"month":8,"riseRate":0.714286,"avgChangeRate":0.085094},{"month":9,"riseRate":0.571429,"avgChangeRate":0.128993},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.068917},{"month":11,"riseRate":0.714286,"avgChangeRate":0.074513},{"month":12,"riseRate":0.571429,"avgChangeRate":0.015266}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}